Novo Nordisk announced the official submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for oral tablet semaglutide.
The FDA on Friday issued a complete response letter regarding a new drug application for oral sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor for ...
SEATTLE - You've heard of CBD, an extract derived from cannabis; the popularity and the touted benefits continue to spread. Now a local scientist is embarking ...
Conatus Pharmaceuticals on Thursday disclosed its lead liver disease drug emricasan missed its primary goal in a Phase 2b study of patients with non-alcoholic ...
In many ways, 2018 was a banner year for new novel drug approvals with 59 drugs approved by the FDA's Center for Drug Evaluation and Research (CDER).
(HealthDay)—Women with recurrent ovarian cancer who receive the poly ADP ribose polymerase (PARP) inhibitor niraparib as maintenance therapy after ...
An intranasal subunit vaccine (SynGEM) that introduces the respiratory syncytial virus (RSV), has demonstrated efficacy in actuating lasting immune responses ...
It's another devastating blow in the search for a treatment for patients living with Alzheimer's disease.